INTRODUCTION:Antipsychotic drugs exert antipsychotic effects by blocking dopamine D2 receptors in the treatment of schizophrenia. However, effects of D2 receptor blockade on neurocognitive function still remain to be elucidated. The objective of this analysis was to evaluate impacts of estimated dopamine D2 receptor occupancy with antipsychotic drugs on several domains of neurocognitive function in patients with schizophrenia in the Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) trial. METHODS: The dataset from the CATIE trial was used in the present analysis. Data were extracted from 410 subjects who were treated withrisperidone, olanzapine, or ziprasidone, received assessments for neurocognitive functions (verbal memory, vigilance, processing speed, reasoning, and working memory) and psychopathology, and provided plasma samples for the measurement of plasma antipsychotic concentrations. D2 receptor occupancy levels on the day of neurocognitive assessment were estimated from plasma antipsychotic concentrations, using population pharmacokinetic analysis and our recently developed model. A multivariate general linear model was used to examine effects of clinical and demographic characteristics, including estimated D2 occupancy levels, on neurocognitive functions. RESULTS: D2 occupancy levels showed significant associations with the vigilance and the summary scores. Neurocognitive functions, including vigilance, were especially impaired in subjects who showed D2 receptor occupancy level of >77%. DISCUSSION: These findings suggest a nonlinear relationship between prescribed antipsychotic doses and overall neurocognitive function and vigilance. This study shows that D2 occupancy above approximately 80% not only increases the risk for extrapyramidal side effects as consistently reported in the literature but also increases the risk for cognitive impairment.
RCT Entities:
INTRODUCTION: Antipsychotic drugs exert antipsychotic effects by blocking dopamine D2 receptors in the treatment of schizophrenia. However, effects of D2 receptor blockade on neurocognitive function still remain to be elucidated. The objective of this analysis was to evaluate impacts of estimated dopamine D2 receptor occupancy with antipsychotic drugs on several domains of neurocognitive function in patients with schizophrenia in the Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) trial. METHODS: The dataset from the CATIE trial was used in the present analysis. Data were extracted from 410 subjects who were treated with risperidone, olanzapine, or ziprasidone, received assessments for neurocognitive functions (verbal memory, vigilance, processing speed, reasoning, and working memory) and psychopathology, and provided plasma samples for the measurement of plasma antipsychotic concentrations. D2 receptor occupancy levels on the day of neurocognitive assessment were estimated from plasma antipsychotic concentrations, using population pharmacokinetic analysis and our recently developed model. A multivariate general linear model was used to examine effects of clinical and demographic characteristics, including estimated D2 occupancy levels, on neurocognitive functions. RESULTS: D2 occupancy levels showed significant associations with the vigilance and the summary scores. Neurocognitive functions, including vigilance, were especially impaired in subjects who showed D2 receptor occupancy level of >77%. DISCUSSION: These findings suggest a nonlinear relationship between prescribed antipsychotic doses and overall neurocognitive function and vigilance. This study shows that D2 occupancy above approximately 80% not only increases the risk for extrapyramidal side effects as consistently reported in the literature but also increases the risk for cognitive impairment.
Authors: Richard S E Keefe; Robert M Bilder; Philip D Harvey; Sonia M Davis; Barton W Palmer; James M Gold; Herbert Y Meltzer; Michael F Green; Del D Miller; Jose M Canive; Lawrence W Adler; Theo C Manschreck; Marvin Swartz; Robert Rosenheck; Diana O Perkins; Trina M Walker; T Scott Stroup; Joseph P McEvoy; Jeffrey A Lieberman Journal: Neuropsychopharmacology Date: 2006-04-19 Impact factor: 7.853
Authors: Kara A Bottiggi; Juan C Salazar; Lei Yu; Allison M Caban-Holt; Melody Ryan; Marta S Mendiondo; Frederick A Schmitt Journal: Am J Geriatr Psychiatry Date: 2006-11 Impact factor: 4.105
Authors: Zahinoor Ismail; Alette M Wessels; Hiroyuki Uchida; Wenzie Ng; David C Mamo; Tarek K Rajji; Bruce G Pollock; Benoit H Mulsant; Robert R Bies Journal: Am J Geriatr Psychiatry Date: 2012-01 Impact factor: 4.105
Authors: Gary G Kay; Mohamed B Abou-Donia; William S Messer; Declan G Murphy; Jack W Tsao; Joseph G Ouslander Journal: J Am Geriatr Soc Date: 2005-12 Impact factor: 5.562
Authors: Shinichiro Nakajima; Hiroyuki Uchida; Robert R Bies; Fernando Caravaggio; Takefumi Suzuki; Eric Plitman; Wanna Mar; Philip Gerretsen; Bruce G Pollock; Benoit H Mulsant; David C Mamo; Ariel Graff-Guerrero Journal: Schizophr Bull Date: 2015-07-28 Impact factor: 9.306
Authors: Dean F Wong; Hiroto Kuwabara; James Robert Brašić; Thomas Stock; Atul Maini; Emily G Gean; Antony Loebel Journal: Psychopharmacology (Berl) Date: 2013-05-07 Impact factor: 4.530
Authors: Tarek K Rajji; Benoit H Mulsant; Shinichiro Nakajima; Fernando Caravaggio; Takefumi Suzuki; Hiroyuki Uchida; Philip Gerretsen; Wanna Mar; Bruce G Pollock; David C Mamo; Ariel Graff-Guerrero Journal: Am J Geriatr Psychiatry Date: 2016-08-02 Impact factor: 4.105
Authors: Gagan Fervaha; Fernando Caravaggio; David C Mamo; Benoit H Mulsant; Bruce G Pollock; Shinichiro Nakajima; Philip Gerretsen; Tarek K Rajji; Wanna Mar; Yusuke Iwata; Eric Plitman; Jun Ku Chung; Gary Remington; Ariel Graff-Guerrero Journal: Psychopharmacology (Berl) Date: 2016-08-24 Impact factor: 4.530
Authors: Jun Ku Chung; Shinichiro Nakajima; Eric Plitman; Yusuke Iwata; Danielle Uy; Philip Gerretsen; Fernando Caravaggio; M Mallar Chakravarty; Ariel Graff-Guerrero Journal: Am J Geriatr Psychiatry Date: 2016-04-29 Impact factor: 4.105